Gold vs US Dollar

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Smith & Nephew Investors - SN.

Share Name	Share Symbol	Market	Stock Type
Smith & Nephew Plc	SN.	London	Ordinary Share

	Price Change	Price Change %	Share Price	Last Trade
	1.40	0.14%	976.20	12:08:30

Open Price	Low Price	High Price	Close Price	Previous Close
982.00	971.00	982.20		974.80

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Top Investor Posts

Top Posts
Posted at 14/11/2024 07:33 by foreverbull FT article Big investors call for break-up of Smith & NephewThree top 20 shareholders say medical devices company should consider spinning off orthopaedics unitSmith and Nephew logoThe UK-headquartered company has been urged to spin off its orthopaedics division © DreamstimeThree major investors are pushing FTSE 100 company Smith & Nephew to consider a break-up of the business, after disappointing results last month reignited concerns about the medical device maker's strategy.The top 20 shareholders told the Financial Times that the UK-headquartered company should spin off its orthopaedics division, which makes replacement hip and knee joints, if management could not improve its performance.Two of the investors said that a private equity firm could be a potential buyer for the division, the largest by sales of the company's three business lines. "If they could find a buyer for the orthopaedic business that would be quite compelling," one of the investors said.Shares in Smith & Nephew have fallen more than 13 per cent since the end of October when it cut its growth forecast for the year, citing poor sales in China linked to changes in the country's procurement policies. It also said it would continue to struggle in 2025.But China accounted for just 5 per cent of sales last year according to its annual report, and investors said the challenges were more widespread, including a loss of market share in the US, where it makes the majority of its sales.Rupert Soames, chair of Smith & Nephew, told the Financial Times: "We have a well-formed strategy and a plan that we are diligently executing?.?.?.?it encompasses all three of our business lines."Swedish activist Cevian took a 5 per cent stake in the company earlier this year, saying it "owns fundamentally attractive businesses", but had failed to create shareholder value.Its shares are down more than 40 per cent over the past five years as it has struggled with high turnover of executives and underperformance in its orthopaedics division.Orthopaedics is the company's largest but slowest-growing division, behind wound management and sports medicine. Growth has been particularly slow in the US, where it has steadily lost market share over the past decade and is now the fourth-largest provider of replacement hips and knees.Figures from the American Joint Replacement Registry show that the company's Genesis product has gone from being used for 10 per cent of knee replacements in 2012 to under 5 per cent in 2023, falling behind the other three major providers, Zimmer BioMet, Stryker and Johnson & Johnson.Deepak Nath, chief executive since April 2022, has launched a 12-point plan to improve performance into 2025, including strengthening its supply chain and launching new orthopaedics technology to win back market share.But two of the investors said there was a lack of urgency to the turnaround efforts and that the board had not been open to alternatives, such as a spin off."The orthopaedics business is the problem child," said one investor. "They are struggling to fix it and there may be a better owner to that asset if they can't turn it around.""The fundamental risk for Smith & Nephew is that the orthopaedic business is the fourth-largest of an oligopoly of four?.?.?.?if they invest the same percentage of sales in research and development as the other three, the absolute investment is lower, and the others will pull ahead," another added.But one fund manager said he did not see the rationale for a break-up: "The orthopaedics business is capital intensive and relies on cash flow from sports medicine and advanced wound management to survive."Disappointing shareholder returns have led to attention from activist investors in the past: US firm Elliott Management mounted an activist campaign at Smith & Nephew in 2017, calling for it to break up the business. Read Full Thread Reply
Posted at 05/11/2024 00:16 by philanderer Jefferies cuts Smith & Nephew target but stays optimistic Jefferies has slashed its target price for medical devices maker Smith & Nephew from 1,400p to 1,250p after challenges in China weighed heavily on third-quarter results. Nevertheless, the broker kept a 'buy' rating on the stock, saying that the shares' valuation is undemanding by historical standards. Smith & Nephew reported on Thursday that it was cutting its 2024 and 2025 guidance on the back of struggles in China, where it was impacted by worse-than-expected headwinds across the surgical businesses. "This is a clear step back as investors were slowly starting to reward management for improved visibility and consistency," Jefferies said in a research note on Monday. "While unhelpful, China setbacks seem temporary and SN is slowly reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts, which support higher, sustainable growth." The stock has dropped by around 20% over the past three months, leaving its close to an all-time low price-to-earnings ratio of just 12.5. Jefferies said it sees "ample room for [a] re-rating". Sharecast Read Full Thread Reply
Posted at 25/10/2024 11:54 by justiceforthemany Deepak needs the boot. Investor relations people are also 💩 Perhaps yanks want it cheap? Read Full Thread Reply
Posted at 27/7/2024 00:41 by foreverbull Https://finance.yahoo.com/news/value-investors-buy-smith-nephew-134014418.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvLnVrLw&guce_referrer_sig=AQAAAHiUvNvWkGtESbuNH-DCZFGA2buU3TGd8l60rVhiPEMunvMoRFpdk5UiN6L5op2aAq1Jb167O-0axJdgGmghMm2vL94_Z8PDWGRC9qbBtFt2TSRLl-LEa68_qztKsp62sW-D4V15uJxg7KfAPHJvjYtIdJJABgcsN8g3LYcm1o2wShould Value Investors Buy Smith & Nephew SNATS (SNN) Stock?Zacks Equity ResearchWed, Jul 24, 2024 at 2:40 PM GMT+12 min readOne company to watch right now is Smith & Nephew SNATS (SNN). SNN is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 14.87. This compares to its industry's average Forward P/E of 20.26. Over the past year, SNN's Forward P/E has been as high as 17.45 and as low as 11.69, with a median of 13.91.SNN is also sporting a PEG ratio of 1.13. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SNN's PEG compares to its industry's average PEG of 2.07. SNN's PEG has been as high as 1.60 and as low as 0.98, with a median of 1.27, all within the past year.Another valuation metric that we should highlight is SNN's P/B ratio of 2.38. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 6.95. Over the past 12 months, SNN's P/B has been as high as 2.61 and as low as 1.80, with a median of 2.19.These are only a few of the key metrics included in Smith & Nephew SNATS's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, SNN looks like an impressive value stock at the moment. Read Full Thread Reply
Posted at 04/7/2024 08:17 by foreverbull Shares in Smith & Nephew PLC (LSE:SN) jumped after it was revealed that activist investor Cevian Capital has built a stake in the replacement hip and knee maker. The Swedish hedge fund, which has previously taken positions in Aviva, Vodafone, Pearson and RSA Insurance, declared a stake of 5.02%.S&N shares, which hit almost a decade low last year and have fallen around 19% over the past 12 months, jumped 6.5% to 1,050.5p in early trades on Thursday. Cevian's strategy is to acquire significant minority ownership positions in European public companies and "work as an owner" to improve value.According to its website, the fund typically acquires stakes in companies that it believes have leading market positions, produce strong cashflows, benefit from robust long-term demand dynamics and "are overlooked, misunderstood or out-of-favor with investors". Read Full Thread Reply
Posted at 04/7/2024 06:47 by bomber13 An activist investor with 5% of S&N may be just what is needed to shake things up a bit ? Read Full Thread Reply
Posted at 26/6/2024 22:23 by justiceforthemany Investors need to be contacting Investor Relations and ask for the CEO Deepak Nath to go. Buck stops at the top. Abysmal. Read Full Thread Reply
Posted at 07/6/2024 06:54 by socionomics The good news for SN investors is that we're heading into Wave 5, so we should break the £20 high in due course. The bad news is that's a 5-6 year move. Might be a little too boring for many, but for me it's an easy SIPP play. DYOR as always. Read Full Thread Reply
Posted at 16/4/2024 12:00 by justiceforthemany Anyone bothered to contact Investor Relations? Read Full Thread Reply
Posted at 28/3/2024 16:47 by justiceforthemany Rather than expressing your unhappiness here stakeholders need to be proactive and speak to Investor Relations Katherine (Head) 07811 270734 Deepak and his frequent share sales needs the boot for one. Has Soames not bought any stock either? Read Full Thread Reply

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions